Loading...
Loading...
RETA| Name | Value |
|---|---|
| Revenues | 0.9M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.9M |
| Operating Expense | 79.5M |
| Operating I/L | -71.5M |
| Other Income/Expense | -14.1M |
| Interest Income | 0.0M |
| Pretax | -85.6M |
| Income Tax Expense | -0.1M |
| Net Income/Loss | -85.5M |
Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for serious or life-threatening diseases. The company's revenue is generated through the development and potential commercialization of various Phase 3 and Phase 2 clinical trial programs, including bardoxolone methyl for chronic kidney disease and pulmonary arterial hypertension, omaveloxolone for Friedreich's ataxia, and other potential treatments for neurological, autoimmune, inflammatory, and fibrotic diseases. Reata also has strategic collaboration agreements with Kyowa Kirin Co., Ltd. and AbbVie Inc. to develop and commercialize its products in specific regions and indications.
